Rezolute Inc Stock

$4.86

1.02% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

US76200L3096

Symbol

RZLT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Software / Internet

Industry

Internet services

Overview Dividends Analysts Charts News Strategies

Rezolute Inc Stock price

$4.86

-2.66 35.37% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

-0.05 1.02%

ISIN

US76200L3096

Symbol

RZLT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Software / Internet

Industry

Internet services

Key metrics

Market capitalization	$281.60m
Enterprise Value	$175.41m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	2.37
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-71.45m
Cash position	$108.27m
EPS (TTM) EPS	$-1.27
P/E forward	negative
Short interest	2.84%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Rezolute Inc Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Rezolute Inc forecast:

10x Buy

100%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Rezolute Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Rezolute Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.03 0.03	92% 92% -
Gross Profit	-0.03 -0.03	92% 92% -
- Selling and Administrative Expenses	15 15	20% 20% -
- Research and Development Expense	56 56	16% 16% -
EBITDA	-71 -71	16% 16% -
- Depreciation and Amortization	0.03 0.03	92% 92% -
EBIT (Operating Income) EBIT	-71 -71	16% 16% -
Net Profit	-69 -69	23% 23% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Rezolute Inc Stock News

Neutral

GlobeNewsWire

●

2 months ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S.

Positive

Reuters

●

3 months ago

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

Rezolute Inc said on Monday the U.S. Food and Drug Administration has removed the partial clinical hold on its late-stage study testing its experimental treatment for low blood sugar.

Neutral

GlobeNewsWire

●

3 months ago

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025 Commencing study startup activities in the U.S.; participant enrollment anticipated in early 2025

More Rezolute Inc News

Company Profile

Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Head office	United States
CEO	Nevan Elam
Employees	59
Founded	2010
Website	www.rezolutebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now